Physician

Lea Kathleen Krekow, MD

According to 2025 Medicare claims, Lea Krekow, MD (NPI: 1982641361) practices medical oncology in the Fort Worth-Arlington-Grapevine, TX market, with the plurality of this provider's patient population coming from Tarrant, TX. This provider's primary affiliated billing organization is TEXAS ONCOLOGY PA (NPI: 1033386578; TIN: 752131429) and primary practice location at 76022-6920. Krekow is affiliated with the UT Southwestern Accountable Care Network (ACO ID: D0211), participating under the REACH model.

Krekow's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 596 traditional Medicare patients, billed 95,923 HCPCS/CPT codes, and received $1,461,385 in Medicare payments. The top billing code was 99213 (Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more). Part D data shows 900 prescription claims across 234 beneficiaries totaling $297,224 in drug costs, led by Letrozole (Letrozole). DME data shows 19 claims. Open Payments data shows 14 records totaling $20,798. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $798,163 and ending at $1,461,385. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $83,397 and ending at $297,224. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	456	60,732	$798,163
2016	644	69,670	$941,351
2017	723	87,767	$1,294,919
2018	655	89,261	$1,323,651
2019	576	124,963	$1,297,427
2020	596	119,331	$1,314,387
2021	570	97,080	$1,018,205
2022	565	76,858	$788,095
2023	561	111,879	$1,283,399
2024	596	95,923	$1,461,385

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	239	1,210	$83,397
2016	241	1,240	$181,816
2017	226	1,187	$635,767
2018	251	1,341	$537,895
2019	253	1,121	$422,785
2020	265	1,166	$443,256
2021	240	1,032	$512,346
2022	233	943	$645,231
2023	231	914	$570,341
2024	234	900	$297,224

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	13	16	$1,116
2016	33	70	$19,835
2017	13	40	$7,904
2018	14	40	$5,048
2019	N/R	90	$10,380
2020	N/R	53	$3,821
2021	N/R	42	$3,262
2022	N/R	N/R	N/R
2023	N/R	26	$4,967
2024	12	19	$2,033

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	259	296	$54
86300	Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3	295	398	$20
80053	Blood test, comprehensive group of blood chemicals	303	477	$10
36415	Insertion of needle into vein for collection of blood sample	238	322	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	293	452	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Letrozole	Letrozole	427	35,378	$10,995
Exemestane	Exemestane	56	4,305	$8,367
Tamoxifen Citrate	Tamoxifen Citrate	148	12,960	$4,529
Anastrozole	Anastrozole	25	2,250	$673
Minoxidil	Minoxidil	36	3,180	$597

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
L8000	Breast prosthesis, mastectomy bra, without integrated breast prosthesis form, any size, any type	N	12	19	$2,033

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	8	$150	Celgene Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	6	$20,648	AstraZeneca Pharmaceuticals LP
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Lea Kathleen Krekow, MD?

Tedicare shows public-source Medicare data for Lea Kathleen Krekow, MD (NPI 1982641361), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Lea Kathleen Krekow, MD have ACO affiliation data?

Lea Kathleen Krekow, MD is shown with ACO affiliation data for UT Southwestern Accountable Care Network (REACH, ACO ID D0211).

What billing organization is linked to Lea Kathleen Krekow, MD?

Lea Kathleen Krekow, MD is linked to TEXAS ONCOLOGY PA (billing NPI 1033386578) in the available physician profile data.

Does Lea Kathleen Krekow, MD have Open Payments data?

Lea Kathleen Krekow, MD has 14 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.